回复：“对‘抗PD-1治疗后大疱性类天疱疮：一项评估对肿瘤反应和生存结果影响的回顾性病例对照研究’的评论” - Suppr

Reply to: "Comment on 'Bullous pemphigoid after anti-PD-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes'".

作者信息

Nelson Caroline A, Singer Sean, Chen Tianqi, Puleo Ashleigh Eberly, Lian Christine G, Wei Erin X, Giobbie-Hurder Anita, Mostaghimi Arash, LeBoeuf Nicole R

机构信息

Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Department of Cutaneous Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

出版信息

J Am Acad Dermatol. 2022 Dec;87(6):e245-e248. doi: 10.1016/j.jaad.2020.05.023. Epub 2020 May 15.

DOI:10.1016/j.jaad.2020.05.023

PMID:32417422

Abstract

摘要

相似文献

Reply to: "Comment on 'Bullous pemphigoid after anti-PD-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes'".回复：“对‘抗PD-1治疗后大疱性类天疱疮：一项评估对肿瘤反应和生存结果影响的回顾性病例对照研究’的评论”

J Am Acad Dermatol. 2022 Dec;87(6):e245-e248. doi: 10.1016/j.jaad.2020.05.023. Epub 2020 May 15.

Comment on "Bullous pemphigoid after anti-PD-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes".关于“抗PD-1治疗后大疱性类天疱疮：一项评估对肿瘤反应和生存结局影响的回顾性病例对照研究”的评论

J Am Acad Dermatol. 2022 Dec;87(6):e249. doi: 10.1016/j.jaad.2020.04.174. Epub 2020 May 13.

Bullous pemphigoid after anti-programmed death-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes.抗程序性死亡-1治疗后发生大疱性类天疱疮：一项评估对肿瘤反应和生存结果影响的回顾性病例对照研究。

J Am Acad Dermatol. 2022 Dec;87(6):1400-1402. doi: 10.1016/j.jaad.2019.12.068. Epub 2020 Jan 10.

Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.PD-1 抑制剂不良事件报告系统中与 PD-1 抑制剂相关的大疱性类天疱疮不良事件的比例分析。

Expert Opin Drug Saf. 2019 Jul;18(7):623-633. doi: 10.1080/14740338.2019.1619693. Epub 2019 May 22.

Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy.抗 PD-1 和抗 PD-L1 治疗相关的大疱性疾病：一项回顾性分析，评估了临床和组织病理学特征、频率以及对癌症治疗的影响。

J Am Acad Dermatol. 2018 Dec;79(6):1081-1088. doi: 10.1016/j.jaad.2018.07.008. Epub 2018 Jul 17.

Response to: "Missed induced bullous pemphigoid: When the anamnesis is the cure," a comment on "Missed drug-induced bullous pemphigoid leads to longer immunosuppression than recognized cases: A 9-year retrospective review".对《漏诊的药物性大疱性类天疱疮：当病史即治疗方法》的回应，这是对《漏诊的药物性大疱性类天疱疮导致免疫抑制时间长于已确诊病例：一项9年回顾性研究》的评论。

J Am Acad Dermatol. 2020 Sep;83(3):e223-e224. doi: 10.1016/j.jaad.2020.05.060. Epub 2020 May 19.

Clinical, biological and histological characteristics of bullous pemphigoid associated with anti-PD-1/PD-L1 therapy: A national retrospective study.抗PD-1/PD-L1治疗相关大疱性类天疱疮的临床、生物学和组织学特征：一项全国性回顾性研究。

J Eur Acad Dermatol Venereol. 2021 Aug;35(8):e511-e514. doi: 10.1111/jdv.17253. Epub 2021 Apr 13.

Evaluation of Risk of Bullous Pemphigoid With Initiation of Dipeptidyl Peptidase-4 Inhibitor vs Second-generation Sulfonylurea.二肽基肽酶-4 抑制剂与第二代磺酰脲类药物起始治疗时大疱性类天疱疮风险评估。

JAMA Dermatol. 2020 Oct 1;156(10):1107-1114. doi: 10.1001/jamadermatol.2020.2158.

Reply to: "Comment on 'Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study' and a case report of glucagon-like peptide-1 receptor agonist-induced bullous pemphigoid".回复：“对‘除二肽基肽酶-4抑制剂外的口服降糖药与大疱性类天疱疮无关：一项芬兰全国性病例对照研究’的评论以及一例胰高血糖素样肽-1受体激动剂诱发大疱性类天疱疮的病例报告”

J Am Acad Dermatol. 2019 Jun;80(6):e191-e192. doi: 10.1016/j.jaad.2019.02.005. Epub 2019 Feb 7.

Reply to: Comment on "Association of bullous pemphigoid with malignancy: A systematic review and meta-analysis".回复：对“大疱性类天疱疮与恶性肿瘤的关联：一项系统评价和荟萃分析”的评论

J Am Acad Dermatol. 2021 Dec;85(6):e345. doi: 10.1016/j.jaad.2017.12.014. Epub 2017 Dec 12.

引用本文的文献

Case report: Bullous pemphigoid associated with sintilimab therapy for pMMR/MSS colorectal cancer.病例报告：信迪利单抗治疗错配修复蛋白缺陷/微卫星稳定的结直肠癌相关的大疱性类天疱疮

Front Oncol. 2023 Mar 14;13:1124730. doi: 10.3389/fonc.2023.1124730. eCollection 2023.

Two rare cases of bullous pemphigoid associated with immune checkpoint inhibitors.两例与免疫检查点抑制剂相关的大疱性类天疱疮罕见病例。

BMJ Case Rep. 2022 Dec 7;15(12):e253059. doi: 10.1136/bcr-2022-253059.

A 72-year-old man with nonhealing facial erosions and bullae.一名72岁男性，面部有经久不愈的糜烂和大疱。

JAAD Case Rep. 2022 Jul 20;27:99-102. doi: 10.1016/j.jdcr.2022.06.026. eCollection 2022 Sep.

Impact of biologic therapy on cancer outcomes in patients with immune checkpoint inhibitor-induced bullous pemphigoid.生物疗法对免疫检查点抑制剂诱导的大疱性类天疱疮患者癌症预后的影响。

J Am Acad Dermatol. 2023 Mar;88(3):670-671. doi: 10.1016/j.jaad.2022.06.1186. Epub 2022 Jun 30.

Skin Manifestation Induced by Immune Checkpoint Inhibitors.免疫检查点抑制剂诱导的皮肤表现

Clin Cosmet Investig Dermatol. 2022 May 10;15:829-841. doi: 10.2147/CCID.S364243. eCollection 2022.

Cutaneous immune-related adverse events among Taiwanese cancer patients receiving immune checkpoint inhibitors link to a survival benefit.台湾癌症患者接受免疫检查点抑制剂治疗后出现的皮肤免疫相关不良反应与生存获益相关。

Sci Rep. 2022 Apr 29;12(1):7021. doi: 10.1038/s41598-022-11128-5.

Dermatologic immune-related adverse events: The toxicity spectrum and recommendations for management.皮肤免疫相关不良事件：毒性谱及管理建议。

Int J Womens Dermatol. 2021 Oct 23;7(5Part A):625-635. doi: 10.1016/j.ijwd.2021.10.005. eCollection 2021 Dec.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reply to: "Comment on 'Bullous pemphigoid after anti-PD-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes'".

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献